Suppr超能文献

白杨素通过抑制乳腺癌细胞中 DNA 双链断裂修复来损害基因组稳定性。

Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells.

机构信息

Shanghai Key Laboratory of Maternal Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.

Department of Gynecology of Shanghai First Maternity & Infant Hospital, School of Medicine, Tongji University, Shanghai, China.

出版信息

Cell Cycle. 2022 Feb;21(4):379-391. doi: 10.1080/15384101.2021.2020434. Epub 2022 Jan 5.

Abstract

Chrysin, a natural compound isolated from various plants, such as the blue passion flower (.), exhibits multiple pharmacological activities, such as antitumor, anti-inflammatory and antioxidant activities. Accumulating evidence shows that chrysin inhibits cancer cell growth by inducing apoptosis and regulating cell cycle arrest. However, whether chrysin is involved in regulating genomic stability and its underlying mechanisms in breast cancer cells have not been determined. Here, we demonstrated that chrysin impairs genomic stability in MCF-7 and BT474 cells, inhibits cell survival and enhances the sensitivity of MCF-7 cells to chemotherapeutic drugs. Further experiments revealed that chrysin impairs DNA double-strand break (DSB) repair, resulting in accumulation of DNA damage. Mechanistic studies showed that chrysin inhibits the recruitment of the key NHEJ factor 53BP1 and delays the recruitment of the HR factor RAD51. Thus, we elucidated novel regulatory mechanisms of chrysin in DSB repair and proposed that a combination of chrysin and chemotherapy has curative potential in breast cancers.

摘要

白杨素是一种从多种植物中分离出来的天然化合物,如蓝西番莲(Passiflora caerulea),具有多种药理活性,如抗肿瘤、抗炎和抗氧化活性。越来越多的证据表明,白杨素通过诱导细胞凋亡和调节细胞周期阻滞来抑制癌细胞生长。然而,白杨素是否参与调节乳腺癌细胞的基因组稳定性及其潜在机制尚不清楚。在这里,我们证明白杨素损害 MCF-7 和 BT474 细胞的基因组稳定性,抑制细胞存活并增强 MCF-7 细胞对化疗药物的敏感性。进一步的实验表明,白杨素损害 DNA 双链断裂(DSB)修复,导致 DNA 损伤的积累。机制研究表明,白杨素抑制关键 NHEJ 因子 53BP1 的募集,并延迟 HR 因子 RAD51 的募集。因此,我们阐明了白杨素在 DSB 修复中的新的调节机制,并提出白杨素与化疗相结合可能对乳腺癌具有治疗潜力。

相似文献

1
Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells.
Cell Cycle. 2022 Feb;21(4):379-391. doi: 10.1080/15384101.2021.2020434. Epub 2022 Jan 5.
3
Multifaceted regulation and functions of 53BP1 in NHEJ‑mediated DSB repair (Review).
Int J Mol Med. 2022 Jul;50(1). doi: 10.3892/ijmm.2022.5145. Epub 2022 May 18.
4
Kinesin Kif2C in regulation of DNA double strand break dynamics and repair.
Elife. 2020 Jan 17;9:e53402. doi: 10.7554/eLife.53402.
5
Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.
PLoS One. 2015 Mar 19;10(3):e0121581. doi: 10.1371/journal.pone.0121581. eCollection 2015.
8
Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1.
J Zhejiang Univ Sci B. 2021 Jan 15;22(1):38-46. doi: 10.1631/jzus.B2000306.
9
DNA double-strand break repair pathway choice and cancer.
DNA Repair (Amst). 2014 Jul;19:169-75. doi: 10.1016/j.dnarep.2014.03.014. Epub 2014 Apr 18.

引用本文的文献

1
Research progress on the anti-cancer mechanisms of edible salty-flavored Chinese materia medica.
Front Pharmacol. 2025 Jun 20;16:1598978. doi: 10.3389/fphar.2025.1598978. eCollection 2025.
2
Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective.
Explor Target Antitumor Ther. 2024;5(3):477-494. doi: 10.37349/etat.2024.00230. Epub 2024 May 23.
4
DNA repair pathways in breast cancer: from mechanisms to clinical applications.
Breast Cancer Res Treat. 2023 Aug;200(3):305-321. doi: 10.1007/s10549-023-06995-z. Epub 2023 Jun 8.
5
Recent Advances in Pharmaceutical Cocrystals: A Focused Review of Flavonoid Cocrystals.
Molecules. 2023 Jan 6;28(2):613. doi: 10.3390/molecules28020613.
6
Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach.
Cancer Drug Resist. 2022 Oct 12;5(4):917-925. doi: 10.20517/cdr.2022.40. eCollection 2022.

本文引用的文献

2
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist. 2020 Mar;25(3):e439-e450. doi: 10.1634/theoncologist.2019-0493. Epub 2019 Nov 25.
3
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Chrysin ameliorates nonalcoholic fatty liver disease in rats.
Naunyn Schmiedebergs Arch Pharmacol. 2019 Dec;392(12):1617-1628. doi: 10.1007/s00210-019-01705-3. Epub 2019 Aug 1.
7
Breast Cancer Treatment: A Review.
JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323.
8
Mitotic slippage: an old tale with a new twist.
Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验